Summary
Global Markets Direct’s, ‘Streptococcus pyogenes Infections - Pipeline Review, H1 2016’, provides an overview of the Streptococcus pyogenes Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Streptococcus pyogenes Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Streptococcus pyogenes Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Streptococcus pyogenes Infections
- The report reviews pipeline therapeutics for Streptococcus pyogenes Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Streptococcus pyogenes Infections therapeutics and enlists all their major and minor projects
- The report assesses Streptococcus pyogenes Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Streptococcus pyogenes Infections
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Streptococcus pyogenes Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Streptococcus pyogenes Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Absynth Biologics Limited
AstraZeneca Plc
Emergent BioSolutions Inc.
Helix BioMedix, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Wellstat Vaccines, LLC
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Streptococcus pyogenes Infections Overview 6
Therapeutics Development 7
Pipeline Products for Streptococcus pyogenes Infections - Overview 7
Pipeline Products for Streptococcus pyogenes Infections - Comparative Analysis 8
Streptococcus pyogenes Infections - Therapeutics under Development by Companies 9
Streptococcus pyogenes Infections - Therapeutics under Investigation by Universities/Institutes 10
Streptococcus pyogenes Infections - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Streptococcus pyogenes Infections - Products under Development by Companies 13
Streptococcus pyogenes Infections - Products under Investigation by Universities/Institutes 14
Streptococcus pyogenes Infections - Companies Involved in Therapeutics Development 15
Absynth Biologics Limited 15
AstraZeneca Plc 16
Emergent BioSolutions Inc. 17
Helix BioMedix, Inc. 18
Sumitomo Dainippon Pharma Co., Ltd. 19
Wellstat Vaccines, LLC 20
Streptococcus pyogenes Infections - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
ATx-201 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AZ-6142 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
EV-035 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
group A Streptococcus vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
HB-1345 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
SM-295291 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SM-369926 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Streptococcus pyogenes vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Streptococcus pyogenes vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
streptococcus pyogenes vaccine (30-valent) - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Streptococcus pyogenes Infections - Recent Pipeline Updates 44
Streptococcus pyogenes Infections - Dormant Projects 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48
List of Tables
Number of Products under Development for Streptococcus pyogenes Infections, H1 2016 7
Number of Products under Development for Streptococcus pyogenes Infections - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Streptococcus pyogenes Infections - Pipeline by Absynth Biologics Limited, H1 2016 15
Streptococcus pyogenes Infections - Pipeline by AstraZeneca Plc, H1 2016 16
Streptococcus pyogenes Infections - Pipeline by Emergent BioSolutions Inc., H1 2016 17
Streptococcus pyogenes Infections - Pipeline by Helix BioMedix, Inc., H1 2016 18
Streptococcus pyogenes Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 19
Streptococcus pyogenes Infections - Pipeline by Wellstat Vaccines, LLC, H1 2016 20
Assessment by Monotherapy Products, H1 2016 21
Number of Products by Stage and Target, H1 2016 23
Number of Products by Stage and Mechanism of Action, H1 2016 25
Number of Products by Stage and Route of Administration, H1 2016 27
Number of Products by Stage and Molecule Type, H1 2016 29
Streptococcus pyogenes Infections Therapeutics - Recent Pipeline Updates, H1 2016 44
Streptococcus pyogenes Infections - Dormant Projects, H1 2016 46
List of Figures
Number of Products under Development for Streptococcus pyogenes Infections, H1 2016 7
Number of Products under Development for Streptococcus pyogenes Infections - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 21
Number of Products by Targets, H1 2016 22
Number of Products by Stage and Targets, H1 2016 22
Number of Products by Mechanism of Actions, H1 2016 24
Number of Products by Stage and Mechanism of Actions, H1 2016 24
Number of Products by Routes of Administration, H1 2016 26
Number of Products by Stage and Routes of Administration, H1 2016 26
Number of Products by Molecule Types, H1 2016 28
Number of Products by Stage and Molecule Types, H1 2016 28
